View in EDS

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.

Saved in:
Bibliographic Details
Title: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.
Authors: Reef DK; Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Grover N; Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Source: AME clinical trials review [AME Clin Trials Rev] 2026 Apr 25; Vol. 4. Date of Electronic Publication: 2025 Dec 17.
Publication Type: Journal Article
Journal Info: Publisher: AME Publishing Company Country of Publication: China NLM ID: 9918994995006676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 3005-6152 (Electronic) Linking ISSN: 30056152 NLM ISO Abbreviation: AME Clin Trials Rev Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42325242
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Reef+DK%22">Reef DK</searchLink>; Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Grover+N%22">Grover N</searchLink>; Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918994995006676%22">AME clinical trials review</searchLink> [AME Clin Trials Rev] 2026 Apr 25; Vol. 4. <i>Date of Electronic Publication: </i>2025 Dec 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22AME+Publishing+Company%22">AME Publishing Company </searchLink><i>Country of Publication: </i>China <i>NLM ID: </i>9918994995006676 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>3005-6152 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2230056152%22">30056152 </searchLink><i>NLM ISO Abbreviation: </i>AME Clin Trials Rev <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42325242
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.21037/actr-25-72
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Reef DK
      – PersonEntity:
          Name:
            NameFull: Grover N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 04
              Text: 2026 Apr 25
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 3005-6152
          Numbering:
            – Type: volume
              Value: 4
          Titles:
            – TitleFull: AME clinical trials review
              Type: main
ResultId 1